Prediction Model for the Recanalization OuTcome Evaluation of Ischemic Stroke Using Multimodal CT (PROTECT)

September 13, 2021 updated by: Xin Lou, Chinese PLA General Hospital

Prediction Model for the Recanalization Outcome Evaluation of Ischemic Stroke Using Multimodal CT

Prediction model for the Recanalization OuTcome Evaluation of ischemic stroke using multimodal CT (PROTECT) study was a multicenter prospective observational study that recruited patients from 13 centers located in 10 provinces across China. The study was to assess the effects of novel imaging biomarkers/ imaging patterns based on multimodel CT for patients selection and outcome prediction in acute ischemic stroke.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Patients Patients with cerebral ischemia symptoms of anterior circulation or posterior circulation onset in 24 hours were included. A neurological evaluation (Modified Rankin Scale and NIHSS); physical examination, including measurement of weight (kg) and vital signs (supine systolic and diastolic blood pressure); time from symptom onset to enrollment were recorded.

Imaging protocols:

CT scan protocols: Non-contrast computed tomography(NCCT) , computed tomography angiography(CTA), computed tomography perfusion(CTP)

Contrast agent:

CTA: Omniscan 40-50ml, 5ml/s; saline solution 50ml, 5ml/s

CTP: Omniscan 50ml, 5ml/s; saline solution 50ml, 5ml/s

Imaging evaluation:

CTA was reviewed and stenosis or occlusive lesions were identified. Parameter maps including cerebral blood flow, cerebral blood volume, mean transit time, the time to the maximum of the residue function derived from CTP were processed by the software Rapid to quantitatively assess infarct core volume and mismatch.

Multiphase CTA was extracted from CTP to evaluate the collateral circulation.

Treatment:

Intravenous recombinant tissue plasminogen activator(rtPA), endovascular therapy, and conventional treatment including neuroprotection, anti-platelet, and statin according to the guideline.

Follow up:

Modified Rankin Scale(mRS) was obtained at 90 days after symptom onset. An imaging follow-up was also recommended within 30 days after symptom onset.

Study Type

Observational

Enrollment (Actual)

862

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Beijing
      • Beijing, Beijing, China, 100853
        • Chinese PLA General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Ischemic stroke patients with sympton onset in 24 hours

Description

Inclusion Criteria:

  • Cerebral ischemic sympton with onset in 24 hours
  • All CT examination performed according to study protocol
  • Signed informed consent obtained from the patient or patient's legally authorized representative

Exclusion Criteria:

  • Acute intracranial hemorrhage
  • Pre-existing medical, the neurological, or psychiatric disease that would confound the neurological, functional, or imaging evaluations
  • Pregnancy
  • Known allergy to iodine previously refractory to pretreatment medications
  • Renal Failure (serum creatinine > 2.0 or Glomerular Filtration Rate < 30)
  • History of severe kidney disease as an adult, including tumor or transplant surgery, or family history of kidney failure
  • Severe cardiac insufficiency

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
stroke
Ischemic stroke patients with sympton onset in 24 hours
Non-contrast computed tomography , computed tomography angiography, computed tomography perfusion imaging

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
90-day functional outcome
Time Frame: 90 days after symptom onset
Assessed by modified Rankin Scale with scores ranging from 0 (no symptoms) to 6 (death)
90 days after symptom onset

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Final infarction volume
Time Frame: within 30 days after symptom onset
Finding the predictive value of novel imaging biomarkers/ imaging patterns on final infarction volume
within 30 days after symptom onset
Percentage of Hemorrhagic Transformation
Time Frame: within 7 days after symptom onset
Symptomatic hemorrhagic transformation after acute ischemic stroke
within 7 days after symptom onset

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 1, 2019

Primary Completion (ACTUAL)

March 30, 2021

Study Completion (ACTUAL)

March 30, 2021

Study Registration Dates

First Submitted

September 12, 2018

First Submitted That Met QC Criteria

September 12, 2018

First Posted (ACTUAL)

September 14, 2018

Study Record Updates

Last Update Posted (ACTUAL)

September 20, 2021

Last Update Submitted That Met QC Criteria

September 13, 2021

Last Verified

September 1, 2021

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke, Acute

Clinical Trials on CT

Subscribe